AHCCCS
Pharmacy and Therapeutics Committee Meeting Minutes
January 16, 2018
12:00PM- 5:00 PM
701 E. Jefferson Phoenix, AZ  85034- Gold Room- 3rd Floor

Members Present:
Loann Nguy
Yvonne Johnson
Dan Lindell
Robert Marotz
Jose Arindaeng
Stephen Borodkin
Cindy Komar
Mohammed Ramadan
Kelly Flannigan
Sandy Brownstein
Shawn McMahon
Joanna Kowalik
Raul Romero

AHCCCS Staff:
Sara Salek
Suzi Berman
Lauren Prole
Robin Davis
Chaz Longwell

Magellan Medicaid Admin:
Lara Frick
Christopher Andrews

Members Absent:
Otto Uhrik
WELCOME AND INTRODUCTIONS: SARA SALEK, M.D., CHIEF MEDICAL OFFICER, AHCCCS

1. Dr. Sara Salek called the meeting to order at 12:03 PM and welcomed committee members, staff, and guest presenters.
   a. P&T Minutes from October 12, 2017 were reviewed.
      i. Motion made to approve meeting minutes by Joanna Kowalik
      ii. Motion seconded by Dan Lindell
      iii. 9 present members voted in favor of approving the minutes
      iv. No present committee members opposed
      v. One present committee member abstained.
   b. AHCCCS P&T Operational Policy Overview

HIV/PrEP Presentation by Dr. Ann Khalsa

1. Journal articles will be sent to committee members for review. This subject will be put to a vote in the April 2018 meeting.
2. The presentation will be available on the AHCCCS website under the Pharmacy Section under Pharmacy & Therapeutics Committee, Agendas and Meetings, January 16, 2018.

SUPPLEMENTAL REBATE CLASS REVIEW

Supplemental Rebate Class Review:

1. Inhaled Glucocorticoids
   a. Clinical review: Lara Frick, PharmD: Magellan
   b. Pharma Testimony: None

Executive Session – Closed to the Public

Preferred Drug Recommendation to the AHCCCS Drug List and/or the AHCCCS Behavioral Health Drug List for the following classes:

1. Inhaled Glucocorticoids
   a. The committee members voted unanimously on the below recommendations for preferred products. No committee members opposed or abstained.
      i. Single Agent Products
         1. Asmanex
2. Flovent HFA
3. Pulmicort Flexhaler (new addition to PDL)
4. Pulmicort Respules
   a. Recommendation is to remove prior authorization for children under the age of 4 for Pulmicort Respules.
5. QVAR has been discontinued by the manufacturer as of February 2018. The product is only available while supplies last.
   ii. Combination Products
      1. Advair Diskus
      2. Advair HFA- only for ages 4-12
      3. Dulera
      4. Symbicort

2. Cytokine and CAM Antagonists – Postponed from October 2017
   a. The committee members voted unanimously on the below recommendations for preferred products. No committee members opposed or abstained.
      i. Enbrel Kit, Syringe and Pen
      ii. Humira Kit and Humira Pen Kit

3. Long Acting Opioid Agonists
   a. The committee members voted unanimously on the below recommendations for preferred products. No committee members opposed or abstained.
      i. Remove Nucynta ER as a preferred agent
      ii. Add Tramadol ER as a preferred agent

NEW DRUG REVIEWS: NON-SUPPLEMENTAL REBATE CLASS: LARA FRICK, PHARM D, MAGELLAN

1. The following new drugs were reviewed for the Non-Supplemental Rebate Class
   a. Gocovri- amantadine
      i. Recommendation is to not add this drug to the AHCCCS Drug list. Gocovri is available through Prior authorization based on medical necessity.
         1. All committee members voted in favor of the recommendations.
         2. No committee members voted against the recommendations.
         3. No committee member abstained.
   b. Vyzulta- latanoprostene bunod
      i. Recommendation is to not add this drug to the AHCCCS Drug list. Vyzulta is available through Prior authorization based on medical necessity.
1. All committee members voted in favor of the recommendations.
2. No committee members voted against the recommendations.
3. No committee member abstained.

c. Solosec- secnidazole
   i. Recommendation is to not add this drug to the AHCCCS Drug list. Solosec is available through Prior authorization based on medical necessity.
      1. Nine committee members voted in favor of the recommendation.
      2. One committee members voted against the recommendation.
      3. No committee member abstained.

d. Xhance- fluticasone propionate
   i. Recommendation is to not add this drug to the AHCCCS Drug list. Xhance is available through Prior authorization based on medical necessity.
      1. All committee members voted in favor of the recommendations.
      2. No committee members voted against the recommendations.
      3. No committee member abstained.

OPEN COMMENTS

2018 MEETING DATES

April 17, 2018
July 17, 2018
October 22, 2018

ADJOURNMENT

The meeting adjourned at 3:32 PM
Minutes recorded by Robin Davis

Suzanne Berman
Suzi Berman, RPh
Director of Pharmacy Services